XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.26.1

Note 4 - Accrued Liabilities | 3 Months Ended
--- | ---
Mar. 31, 2026
Notes to Financial Statements |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 4. Accrued Liabilities Accrued liabilities consisted of the following (in thousands):
|  | March 31, 2026 |  |  | December 31, 2025 |
Accrued compensation-related costs |  | $ | 2,701 |  |  | $ | 1,979 |
Accrued research and development services |  |  | 1,190 |  |  |  | 877 |
Accrued professional services |  |  | 324 |  |  |  | 357 |
Accrued severance |  |  | 584 |  |  |  | — |
Accrued other |  |  | 609 |  |  |  | 363 |
Total accrued liabilities |  | $ | 5,408 |  |  | $ | 3,576 |
In March 2026, the Company announced a strategic and organizational realignment to prioritize and accelerate the development of its nsPFA electrophysiology catheters and other cardiac devices for the treatment of atrial fibrillation (the “2026 Realignment”). In connection with the 2026 Realignment, the Company recognized severance and one-time termination expenses of $0.6 million with less than $0.1 million in payments remitted during the three months ended March 31, 2026.

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration